London-listed Poolbeg Pharma has received regulatory approval in the UK to proceed with human clinical trials of its influenza drug POLB 001.
The company, which spun out from Dublin-listed pharmaceutical services business Open Orphan last year, said the approval marked a significant milestone and that it had delivered on its promise to bring the drug, its lead asset, to trial by the summer of 2022.
Aimed at severe influenza, the drug is a small molecule immunomodulator, that “addresses an unmet need” in treatment of the illness, said Jeremy Skillington, chief executive of Poolbeg, in a statement.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
